EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review

Guofa Zhao, Guiliang Han, Xiaomei Yang, Youchao Jia

Frontiers in Oncology · 11.05.2026 · 16

DOI: 10.3389/fonc.2026.1791245 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 11.05.2026. Verfasst von Guofa Zhao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Baoding, Hebei…. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A 78-year-old female with a history of multiple comorbidities was admitted due to a 20-year-old skin mass in the right temporal region with ulceration for more than 2 months. Porocarcinoma (PC) was confirmed by pathological and immunohistochemical examination of surgically resected tissue. The patient developed rapid recurrence after tumor resection and received 5 cycles of penpulimab combined with nab-paclitaxel. Efficacy was evaluated as a partial response (PR) after 2 cycles, stable disease (SD) with minor regression after 4 cycles, and progressive disease (PD) after 5 cycles. Subsequent treatment with anlotinib hydrochloride capsules combined with local radiotherapy was administered, and the patient ultimately succumbed to the disease. Emerging evidence in recent years has highlighted the potential of immune checkpoint blockers for rare cutaneous malignancies. Our case report demonstrates that combination therapy with an anti-programmed death-1 (PD-1) monoclonal antibody and chemotherapy exhibits therapeutic efficacy in PC. During the entire treatment course, an initial response was achieved followed by acquired resistance, with the best overall response being PR, suggesting that this combination regimen may serve as one of the viable therapeutic options for this refractory malignancy. This study aims to enhance the understanding of the diagnostic and therapeutic challenges of PC.

Schlagwörter

Stichwörter der Autor:innen

case reportdiagnosisliterature reviewporocarcinomatreatment

Autor:innen und Institutionen

  • Department of Medical Oncology, Affiliated Hospital of Hebei University, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Baoding, Hebei, China.

Zitieren

APA

Zhao, G., Han, G., Yang, X., & Jia, Y. (2026). Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1791245

Vancouver

Zhao G, Han G, Yang X, Jia Y. Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1791245

BibTeX
@article{Zhao2026,
  author = {Zhao, Guofa and Han, Guiliang and Yang, Xiaomei and Jia, Youchao},
  title = {Anti-PD-1 monoclonal antibody combined with chemotherapy for porocarcinoma: a case report and literature review},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1791245}
}
Kostenlos starten →